Immunostimulant Market to Exceed $288 Billion by 2034 with 9.9% CAGR Growth The global immunostimulant market is projected to grow from $111.97 billion in 2024 to $288.82 billion by 2034, showcasing a robust CAGR of 9.9%.

Immunostimulant Market to Exceed $288 Billion by 2034 with 9.9% CAGR Growth #None #Market_Growth #Vaccine_Development #Immunostimulant

Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President Clover Biopharmaceuticals announces Nicholas Jackson, Ph.D., as President of Global R&D and Alliances to spearhead vaccine development and collaborations.

Clover Biopharmaceuticals Welcomes Nicholas Jackson, Ph.D., as Global R&D President #China #Shanghai #Vaccine_Development #Clover_Biopharma #Nicholas_Jackson

Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections Glycovax Pharma partners with NRC and Université de Montréal to create a groundbreaking vaccine for Pseudomonas aeruginosa infections, supported by Quebec funding.

Collaborative Breakthrough in Vaccine Development Against Pseudomonas Aeruginosa Infections #Canada #Montreal #Vaccine_Development #Glycovax_Pharma #Pseudomonas_aeruginosa

Dr. Stefan Kappe Appointed Director of Vaccine Development at University of Maryland Distinguished researcher Dr. Stefan Kappe has been appointed as the new director of the Center for Vaccine Development. He aims to innovate malaria vaccines and improve public health.

Dr. Stefan Kappe Appointed Director of Vaccine Development at University of Maryland #United_States #Baltimore #Vaccine_Development #Stefan_Kappe #Malaria_Research

Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections Glycovax Pharma has received approval from the National Research Council of Canada to further develop a vaccine targeting deadly Pseudomonas aeruginosa infections.

Glycovax Pharma Secures License for Vaccine Development Against Pseudomonas Aeruginosa Infections #Canada #Montreal #Vaccine_Development #Glycovax_Pharma #Pseudomonas_aeruginosa

Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio Centivax Inc. has successfully raised $45 million in an oversubscribed Series A funding round aimed at developing a universal flu vaccine and expanding their immunology portfolio.

Centivax Secures $45 Million Funding to Develop Universal Flu Vaccine and Expand Immunology Portfolio #United_States #South_San_Francisco #Vaccine_Development #Centivax #Universal_Immunity

Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines Glycovax Pharma has announced the large-scale production of sulfated lactosyl archaeol (SLA) adjuvant, enhancing vaccine efficacy globally.

Glycovax Pharma Introduces a Next-Generation SLA Adjuvant for Vaccines #Canada #Montreal #Vaccine_Development #Glycovax #SLA_Adjuvant

Abu Dhabi and Sanofi Form Strategic Alliance to Advance Vaccine Development The Department of Health in Abu Dhabi partners with Sanofi to accelerate global vaccine development, enhancing health innovation in the region.

Abu Dhabi and Sanofi Form Strategic Alliance to Advance Vaccine Development #Abu_Dhabi #United_Arab_Emirates #Sanofi #Vaccine_Development

Benchling and Merck: Partnering to Transform Vaccine Bioanalysis with Innovative Software Solutions Benchling has announced a strategic collaboration with Merck to integrate a software framework that enhances bioanalytical workflows across vaccine development. This partnership aims to improve data management and compliance.

Benchling and Merck: Partnering to Transform Vaccine Bioanalysis with Innovative Software Solutions #United_States #San_Francisco #Merck #Vaccine_Development #Benchling

Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives Dynavax Technologies reports impressive Q1 2025 financials with significant growth in HEPLISAV-B revenue, alongside announcements of new vaccine development initiatives.

Dynavax Technologies Unveils Strong Q1 2025 Financial Results and Promising New Vaccine Initiatives #United_States #Emeryville #Vaccine_Development #Dynavax #HEPLISAV-B

SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns SK bioscience collaborates with Korea Disease Control and Prevention Agency to create a rapid-response avian influenza vaccine to enhance global health security.

SK bioscience Partners with Korea to Develop Innovative Avian Flu Vaccine Amid Pandemic Concerns #South_Korea #Seongnam #Avian_Influenza #SK_bioscience #Vaccine_Development

Primrose Bio Partners with Serum Institute to Create a Multi-Antigen Vaccine Primrose Bio and Serum Institute of India join forces to develop a cutting-edge multi-antigen vaccine aimed at global health challenges.

Primrose Bio Partners with Serum Institute to Create a Multi-Antigen Vaccine #India #Pune #Vaccine_Development #Primrose_Bio #Serum_Institute

DIOSynVax Launches Advisory Committee to Advance Next-Gen Flu Vaccines DIOSynVax establishes a committee to enhance the development of its innovative avian influenza vaccines, focusing on safety and broader protection.

DIOSynVax Launches Advisory Committee to Advance Next-Gen Flu Vaccines #Cambridge #United_Kingdom #DIOSynVax #Avian_Flu #Vaccine_Development